|
Pfizer cancer drug takes big step toward fateful FDA decision
FierceBiotech After wrapping up an orphan drug designation and fast track status late last year, Pfizer can now add a priority review stamp to its list of accomplishments for crizotinib, its late-stage lung cancer drug which represents one of the Big Pharma's … Pfizer's Application for Cancer Drug Accepted by FDA Pfizer Files NDA For Lung Cancer Drug Crizotinib With FDA, Japan – Update Pfizer Lung Cancer Drug to Get Priority Review |
View full post on lung cancer – Google News
